FindTrial
Sign In

To explore the mechanism of abnormal activation of different immune cells in patients with systemic lupus erythematosus (SLE) based on multi-omics high-throughput joint analysis

To explore the mechanism of abnormal activation of different immune cells in patients with systemic lupus erythematosus (SLE) based on multi-omics high-throughput joint analysis

Status
Unknown
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071234
Enrollment
Unknown
Registered
2023-05-09
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

healthy donor group:None
active-SLE patient group:None
non-active-SLE group:None

Sponsors

The First People's Hospital of Ji'ning
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. All SLE patients were diagnosed by at least two dermatologists or rheumatologists according to the classification criteria of American College of Rheumatology (ACR) in 1997. 2. Aged 15-50 years. 3. Female.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
General clinical data;RNA-seq transcriptome;Metabolomics analysis;FCM (flow cytometry);—

Countries

China

Contacts

Public ContactShi Dongmei

The First People's Hospital of Ji'ning

shidongmei28@163.com+86 186 7876 9757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026